According to the latest earnings results, Hemo Organic reported a standalone net loss of ₹0.74 crore for the quarter ended June 30, 2026, representing a significant improvement from the net loss of ₹0.86 crore recorded in the corresponding quarter of the previous year. The company's financial performance showed substantial sequential improvement despite the continued losses.
The latest results show basic loss per share from continuing operations of ₹0.21 compared to ₹0.25 a year ago, while diluted loss per share from continuing operations was ₹0.21 compared to ₹0.25 a year ago. This improvement in per share metrics indicates better capital efficiency despite the overall loss increase.
As reported by Business Standard, Hemo Organic reported no sales during the quarter ended June 2026, which was consistent with the zero sales recorded in the previous quarter ended June 2025. The absence of revenue generation continues to impact the company's financial performance, contributing to the reported losses.
The company's net loss of ₹0.74 crore in Q1 FY27 represents a 12.5% improvement compared to the net loss of ₹0.86 crore reported in the corresponding quarter of the previous financial year. This sequential improvement indicates some operational efficiency gains despite the continued revenue challenges and increased absolute loss amount.
